Literature DB >> 3531428

Pharmacological properties of immuno-isolated neuronal nicotinic receptors.

P Whiting, J Lindstrom.   

Abstract

Recently we immunoaffinity-purified an ACh receptor from chicken brain using a monoclonal antibody raised against receptors from fish electric organ (Whiting and Lindstrom, 1986). This neuronal receptor could be affinity-labeled with 3H-bromoacetylcholine, and antisera to it specifically blocked ACh-induced depolarization of chicken ciliary ganglion cells. Here we show that this neuronal ACh receptor binds 3H-nicotine with high affinity (KD = 6.61 +/- 0.13 nM). 3H-Nicotine binding was blocked by various nicotinic cholinergic ligands but not by alpha-bungarotoxin or the muscarinic antagonist atropine. Binding was also blocked by affinity labeling the receptor with bromoacetylcholine (after reduction by dithiothreitol). Additionally, we were able to use rat antisera raised against the chicken brain receptor to isolate a component from detergent extracts of rat brain that also bound 3H-nicotine with high affinity (KD = 1.5 nM). The pharmacology of this putative ACh receptor from rat brain was almost identical to the receptor from chicken brain, and its regional distribution was in good agreement with that of 3H-nicotine binding to rodent brain membranes reported by other workers. Thus, by analogy to the receptor we have purified and characterized from chicken brain, this nicotine-binding component from rat brain is probably a functional mammalian neuronal nicotinic ACh receptor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531428      PMCID: PMC6568798     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  21 in total

Review 1.  Immunohistochemistry of cholinergic receptors.

Authors:  H Schröder
Journal:  Anat Embryol (Berl)       Date:  1992-10

2.  Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines.

Authors:  B Chini; F Clementi; N Hukovic; E Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

3.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 4.  Neuroimaging, genetics and the treatment of nicotine addiction.

Authors:  Riju Ray; James Loughead; Ze Wang; John Detre; Edward Yang; Ruben Gur; Caryn Lerman
Journal:  Behav Brain Res       Date:  2008-06-05       Impact factor: 3.332

Review 5.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

6.  Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of alpha3beta4, a novel subtype in the mammalian nervous system.

Authors:  C M Flores; R M DeCamp; S Kilo; S W Rogers; K M Hargreaves
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

7.  Expression of neuronal acetylcholine nicotinic receptor alpha 4 and beta 2 subunits during postnatal development of the rat brain.

Authors:  M Cimino; P Marini; S Colombo; M Andena; F Cattabeni; D Fornasari; F Clementi
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 8.  Regulation of nicotinic acetylcholine receptors by protein phosphorylation.

Authors:  K Miles; R L Huganir
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

Review 9.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

10.  The hippocampus and cingulate cortex differentially mediate the effects of nicotine on learning versus on ethanol-induced learning deficits through different effects at nicotinic receptors.

Authors:  Danielle Gulick; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2009-04-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.